Home » Topics » Disease categories and therapies » Immune

Immune
RSS

Acambis on track to begin phase III trials of ChimeriVax-JE by year-end

Aug. 31, 2005

Acambis and VIB team up on flu vaccine development

Aug. 17, 2005

Halofuginone modulates T-cell functional activity

Aug. 16, 2005

European authorities approve phase III studies of Japanese encephalitis vaccine

Aug. 11, 2005

Novel immunomodulatory agents disclosed in recent patents

Aug. 9, 2005

KBMA vaccines: novel strategy for safe protective immunity

Aug. 9, 2005

Withdrawal of Infanrix HepB marketing authorization in Europe

Aug. 8, 2005

CytoGenix and Aldevron collaborate on DNA vaccine technology

Aug. 8, 2005

CholeraGarde reported safe and immunogenic in children and infants

Aug. 4, 2005

IL-24's role in immune regulation

Aug. 2, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...